With its approval in Norway, more early-stage breast cancer patients can now use the Oncotype DX Breast Recurrence® Score test to help guide their treatment decisions. Read more: https://lnkd.in/gaYbduGh
Exact Sciences
Biotechnology Research
Madison, Wisconsin 109,593 followers
Changing the way we think about detecting and treating cancer.
About us
At Exact Sciences, our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. We're hiring! Our organization offers something for everyone, at all stages of careers and from all backgrounds. Let's take on cancer, together.
- Website
-
http://exactsciences.com
External link for Exact Sciences
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Madison, Wisconsin
- Type
- Public Company
- Specialties
- Colon cancer screening, Screening test research and development, Non-invasive cancer screening, Precision oncology, and Genomic testing
Locations
Employees at Exact Sciences
Updates
-
Last week, our team in Zug, Switzerland officially moved into our new international headquarters. The state-of-the-art space is designed to foster stronger connection across our teams. We’re energized by this fresh space and look forward to what’s ahead! #WeAreExact
-
“Reunited and it feels so good...” 🎶 How fun it is to watch the original UPS driver who delivered the Cologuard® test kits to Exact Sciences’ laboratories reunite with members of the first-ever specimen processing team. See more below! #10YearsofCologuard
-
For the past decade, the Cologuard® test has helped millions of average risk adults get screened for colorectal cancer. And for some patients, like Yla and Katie, the results changed their life. Hear how their diagnoses have altered their perspectives via Katie Couric Media: https://bit.ly/3z1baiz #10YearsofCologuard
-
Earlier cancer detection changes lives. In just 10 years, the Cologuard® test has been used more than 16 million times, helping average risk patients and their families make more time for the moments that matter. Learn more: https://bit.ly/473HaiA #10YearsofCologuard
-
Innovation is one of our core values at Exact Sciences. New ideas enable us to work toward our purpose of helping eradicate cancer. Find out how fresh thinking from students at the Savannah College of Art and Design, Arizona State University, and University of Wisconsin-Madison revealed even more ways to help support our patients: https://bit.ly/3T1Obut
-
From a groundbreaking idea to an FDA-approved screening tool for average risk patients, the growth of the Cologuard® test was no small feat. Hear some of the unforgettable moments from the Cologuard test’s first 10 years, as told by the team that helped make it happen: https://lnkd.in/gTB2xsR5 #10YearsofCologuard
-
In the final episode of our #10YearsofCologuard series, ten years have passed since Exact Sciences processed its first Cologuard® test. Patients, physicians, and the Exact Sciences team reflect on the test’s impact and look ahead to the next chapter in Cologuard history. Watch the full series here: https://bit.ly/3AyCUvj
-
In episode 4 of our #10YearsofCologuard series, Exact Sciences and the Cologuard® brand have a pop culture moment. A high-profile annual event brings together advocates for screening and builds community among those touched by colorectal cancer. The company works to reach people who remain unscreened.
-
In episode 3 of our #10YearsofCologuard series, the Exact Sciences team pulls together to address a staggering setback and figures out how to move forward. The company introduces a surprising method for promoting the Cologuard® test to customers. As demand for the test skyrockets, the company steps up to respond.
Affiliated pages
Similar pages
Browse jobs
Stock
EXAS
NASDAQ
20 minutes delay
$64.12
5.74 (9.832%)
- Open
- 58.46
- Low
- 57.51
- High
- 65.51
Data from Refinitiv
See more info on